Peter Kohlhepp practices intellectual property law focusing on high-stakes patent litigation and post-grant proceedings. His work spans a variety of technologies, including medical devices, automotive technology, pharmaceuticals and nutraceuticals, medical diagnostics, telecommunications, and energy.
Peter has extensive experience representing clients before the US Patent Trial and Appeal Board (USPTO), including frequently delivering successful oral arguments before Board panels. In a significant inter partes review (IPR), Peter helped a client successfully fend off 17 IPRs challenging a key patent portfolio. Peter also uses his IPR experience to provide clients with creative strategies for leveraging USPTO Board proceedings in US District Court litigation. Peter has argued matters before US District Courts and the Federal Circuit.
In addition to patent and IPR disputes, Peter helps clients with pre-acquisition due diligence, intellectual property licenses, and freedom to operate opinions. Recent examples include providing due diligence for a potential acquisition in the medical and diagnostics field, analyzing patent risks for a prospective new medical device, and helping negotiate licenses concerning CRISPR-Cas9 technology.
Before joining Carlson Caspers, Peter was a judicial extern for the Honorable Judge John Tunheim of the US District Court for the District of Minnesota.
Peter also works with the Children’s Law Center of Minnesota to represent and advocate for children in Minnesota foster care. Peter has repeatedly been named a “Rising Star” in Minnesota Super Lawyers®.
University of Minnesota Law School
J.D., magna cum laude
Managing/Research Editor, Minnesota Law Review
University of Wisconsin
B.S., Engineering Mechanics
Minnesota Supreme Court
U.S. District Court for the District of Minnesota
Peter M. Kohlhepp, Note, “When the Invention is an Inventor: Revitalizing Patentable Subject Matter to Exclude Unpredictable Processes,” 93 Minnesota Law Review 779 (2008).
Susan M. Wolf, Rishi Gupta, and Peter Kohlhepp, “Gene Therapy Oversight: Lessons for Nanobiotechnology,” 37 Journal of Law, Medicine & Ethics 659 (2009).